...
search icon
tvrd-img

Tvardi Therapeutics, Inc., Common Stock

TVRD

NAQ

$25.69

-$0.29

(-1.12%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$243.20M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
19.30K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$8.14 L
$34.31 H
$25.69

About Tvardi Therapeutics, Inc., Common Stock

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameTVRDSectorS&P500
1-Week Return-10.3%-1.35%0.18%
1-Month Return10.12%-0.27%2.8%
3-Month Return3.01%-4.3%14.55%
6-Month Return70.92%-8.76%4.96%
1-Year Return99.89%-10.49%17.23%
3-Year Return-91.34%2.29%54.62%
5-Year Return-95.79%26.65%96.2%
10-Year Return-96.34%76.53%202.11%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue135.08M23.03M--7.14M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":17.05,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":5.28,"profit":true}]
Cost of Revenue-1.55M--812.00K[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":52.25,"profit":true}]
Gross Profit-21.47M--6.33M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":29.45,"profit":true}]
Gross Margin-93.25%--88.62%[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":95.04,"profit":true}]
Operating Expenses128.68M110.56M21.19M18.66M62.11M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":85.91,"profit":true},{"date":"2022-12-31","value":16.47,"profit":true},{"date":"2023-12-31","value":14.5,"profit":true},{"date":"2024-12-31","value":48.26,"profit":true}]
Operating Income5.38M(89.08M)(21.19M)(18.66M)(55.78M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-1654.28,"profit":false},{"date":"2022-12-31","value":-393.56,"profit":false},{"date":"2023-12-31","value":-346.61,"profit":false},{"date":"2024-12-31","value":-1035.86,"profit":false}]
Total Non-Operating Income/Expense--1.30M2.64M-[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":49.39,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Pre-Tax Income7.72M(88.44M)(20.54M)(17.35M)(71.27M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-1145.76,"profit":false},{"date":"2022-12-31","value":-266.12,"profit":false},{"date":"2023-12-31","value":-224.73,"profit":false},{"date":"2024-12-31","value":-923.24,"profit":false}]
Income Taxes(691.00K)---(398.00K)[{"date":"2020-12-31","value":-69100000,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":-39800000,"profit":false}]
Income After Taxes-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations--(20.54M)(17.35M)-[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-2054200000,"profit":false},{"date":"2023-12-31","value":-1734700000,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income8.41M(88.44M)(20.54M)(17.35M)(70.87M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-1051.62,"profit":false},{"date":"2022-12-31","value":-244.26,"profit":false},{"date":"2023-12-31","value":-206.27,"profit":false},{"date":"2024-12-31","value":-842.65,"profit":false}]
EPS (Diluted)2.91(62.42)(57.34)(78.78)(46.64)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-2143.12,"profit":false},{"date":"2022-12-31","value":-1968.73,"profit":false},{"date":"2023-12-31","value":-2704.78,"profit":false},{"date":"2024-12-31","value":-1601.31,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

TVRD
Cash Ratio 28.54
Current Ratio 32.48
Quick Ratio 31.73

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

TVRD
ROA (LTM) 0.00%
ROE (LTM) 0.00%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

TVRD
Debt Ratio Lower is generally better. Negative is bad. 1.21
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.21

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

TVRD
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 0.00
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Tvardi Therapeutics, Inc. share price today?

Tvardi Therapeutics, Inc. (TVRD) share price today is $25.69

Can Indians buy Tvardi Therapeutics, Inc. shares?

Yes, Indians can buy shares of Tvardi Therapeutics, Inc. (TVRD) on Vested. To buy Tvardi Therapeutics, Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TVRD stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Tvardi Therapeutics, Inc. be purchased?

Yes, you can purchase fractional shares of Tvardi Therapeutics, Inc. (TVRD) via the Vested app. You can start investing in Tvardi Therapeutics, Inc. (TVRD) with a minimum investment of $1.

How to invest in Tvardi Therapeutics, Inc. shares from India?

You can invest in shares of Tvardi Therapeutics, Inc. (TVRD) via Vested in three simple steps:

  • Click on Sign Up or Invest in TVRD stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Tvardi Therapeutics, Inc. shares
What is Tvardi Therapeutics, Inc. 52-week high and low stock price?

The 52-week high price of Tvardi Therapeutics, Inc. (TVRD) is $34.31. The 52-week low price of Tvardi Therapeutics, Inc. (TVRD) is $8.14.

What is Tvardi Therapeutics, Inc. price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Tvardi Therapeutics, Inc. (TVRD) is 0.00

What is the Market Cap of Tvardi Therapeutics, Inc.?

The market capitalization of Tvardi Therapeutics, Inc. (TVRD) is $243.20M

What is Tvardi Therapeutics, Inc.’s stock symbol?

The stock symbol (or ticker) of Tvardi Therapeutics, Inc. is TVRD

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top